Cox-2 gene polymorphism and IL-6 levels in coronary artery disease

Ol, Kevser Kuşat; Ağaçhan, Bedia; Görmüş, Uzay; Toptaş, Bahar; İsbır, Turgay

doi:10.4238/vol10-2gmr967

Cited by 15 publications

(8 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A possible reason for the discrepancy is that the clinical role of COX-2 in inflammation may be dual by initiating the process of inflammation and then later aiding in its resolution. The effects of COX-2 genotypes in the inflammatory response through variations in COX-production have been shown with relation to C-reactive protein [32] and IL-6 [34]. In particular, PEG2 is important in regulating IL-6 production and COX-2 inhibitors have been shown to be useful in controlling fibroblast IL-6 production.…”

Section: Discussionmentioning

confidence: 99%

Association between COX-2 rs 6681231 Genotype and Interleukin-6 in Periodontal Connective Tissue. A Pilot Study

et al. 2014

View full text Add to dashboard Cite

ObjectivesThe aim of this pilot study was to investigate associations between IL-6 and COX-2 expression in gingival biopsies and both clinical diagnosis and genotypes in the IL-6 and COX-2 genes.DesignA case-control study included 41 gingival biopsies obtained from Caucasian patients grouped according to clinical diagnosis of gingival health (n = 10), gingivitis (n = 15) or chronic periodontitis (n = 16). Immunohistochemistry analyses were performed to determine COX-2 expression in lamina propria, IL-6 expression in lamina propria and gingival epithelium and level of inflammatory cell infiltrate. Individual DNA was extracted and genotyped by real-time PCR for IL6 SNPs rs 2069827 and rs 2069825 and for COX-2 rs 6681231.ResultsThe percentage of cellular COX-2 expression was associated with the extent of periodontal disease (Arbes index p = 0.026) and inflammatory infiltrate (p<0.0001). No association was observed between IL6 haplotypes and cells positive to IL-6 or COX-2 in gingival tissues. The COX-2 rs 6681231 was associated with cells positive to IL-6 in the connective tissue (p = 0.032).ConclusionsCOX-2 expression in gingival tissues may be a marker of periodontal disease severity. COX-2 rs 6681231 may be associated with IL-6 local production in gingival tissues.

show abstract

Section: Discussionmentioning

confidence: 99%

Association between COX-2 rs 6681231 Genotype and Interleukin-6 in Periodontal Connective Tissue. A Pilot Study

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The response rate is almost identical to what has been observed in the pivotal phase III study with adalimumab where 71% of patients achieved PASI 75. 10 Atherosclerosis is an inflammatory disease [13][14][15][16][17][18][19] and patients with different clinical atherosclerotic manifestations are faced with persistent vascular risk despite our current armamentarium. Anti-inflammatory therapies are presently being assessed to reduce further the risk of myocardial infarction and stroke of patients with established vascular disease.…”

Section: Discussionmentioning

confidence: 99%

Effects of the Tumor Necrosis Factor-α Antagonist Adalimumab on Arterial Inflammation Assessed by Positron Emission Tomography in Patients With Psoriasis

Bissonnette

Tardif

Harel

et al. 2013

Circ: Cardiovascular Imaging

View full text Add to dashboard Cite

P soriasis is a chronic immune-mediated disease affecting up to 3% of the population.1 Skin and joint inflammation are the hallmarks of psoriasis and an increase in the number of T lymphocytes, antigen presenting cells, macrophages, and neutrophils is found in psoriatic plaques. 2 The complex interplay between inflammatory cells and keratinocytes induces epidermal proliferation resulting in the typical indurated, scaly, and erythematous plaques of psoriasis.3 Psoriasis has been shown to increase the risk of myocardial infarction and stroke. [4][5][6][7] Psoriasis treatments include topical corticosteroids, vitamin D analogs and phototherapy and also systemic anti-inflammatory agents, such as methotrexate, cyclosporin, or biological agents targeting tumor necrosis factor-α (TNF-α) or interleukin (IL)-12/IL-23. 8 These systemic agents all have a profound effect on skin and joint inflammation. Clinical Perspective on p 90Atherosclerosis is also an inflammatory disease. 9 We hypothesized that treatment-induced reduction in the local inflammatory process in patients with psoriasis would be associated with decreased vascular inflammation as assessed by positron emission tomography/computed tomography (PET/CT). Methods Study Design and PatientsThis was an investigator-initiated, single-center, single-blind (cardiologist and all staff involved in vascular imaging and analysis were Background-Psoriasis is a chronic inflammatory disease associated with increased risks of myocardial infarction and stroke. Systemic treatments for moderate to severe psoriasis can reduce skin and joint inflammation; however, their effects on vascular inflammation are unknown. Methods and Results-This randomized, controlled trial included 30 patients with moderate to severe psoriasis and a history, or multiple risk factors, of coronary atherosclerosis. Patients were randomized (2:1) to receive either adalimumab subcutaneously for 4 months or to control nonsystemic treatment (topical therapies or phototherapy). Vascular inflammation was measured in the carotid artery and ascending aorta at baseline and week 15, by

show abstract

“…More recent studies on the effect of rs1800795 on transcription factor binding have shown that -174G>C transversion gates the GATA1 access to IL-6 promoter, thereby linking this single nucleotide polymorphism (SNP) to differential risk of inflammation-related diseases such as prostate cancer (Cole et al, 2010). Several of the polymorphisms located in the IL-6 promoter region have also been studied in various disease conditions, i.e., coronary artery disease, asthma, rectal cancer, neuroblastoma, and juvenile arthritis (Corvol et al, 2009; Lagmay et al, 2009; Slattery et al, 2009; Ol et al, 2011). The effect of IL-6 promoter haplotype (-597G>A, -572G>C and -174G>C) has also been shown to have a significant effect on transcriptional regulation and disease association (Cussigh et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

-174G/C polymorphism in the interleukin-6 promoter is differently associated with prostate cancer incidence depending on race

2014

View full text Add to dashboard Cite

Interleukin-6 (IL-6), a pro-inflammatory cytokine, is involved in prostate cancer progression, including androgen independence. Serum IL-6 levels also correlate with prostate tumor burden, prostate-specific antigen levels and metastasis. Since circulating cytokine levels vary considerably inter-individually, such variation could be linked to genetic factors, including genetic polymorphism. The -174G>C/rs1800795 polymorphism in the IL-6 promoter is functionally relevant in terms of transcriptional regulation and disease association. We investigated a possible association of the -174G/C polymorphism with prostate cancer. Since significant racial disparities exist in prostate cancer incidence, we also investigated this association between the -174G/C polymorphism and prostate cancer in Caucasians and African-Americans, separately. Direct sequencing of the PCR amplicon from genomic DNA was used for genotyping rs1800795 in all subjects [age-matched controls (N = 140) and prostate cancer patients (N = 164)]. Sample size and power was calculated using the PGA software. We found the GG genotype to be associated with increased risk of prostate cancer in Caucasian subjects, whereas the CC genotype was associated with increased risk in the African-American sample set. Such a dimorphic genotypic association with cancer and race is unique and suggests a complex gene-gene and gene-environment interaction.

show abstract

Cox-2 gene polymorphism and IL-6 levels in coronary artery disease

Cited by 15 publications

References 22 publications

Association between COX-2 rs 6681231 Genotype and Interleukin-6 in Periodontal Connective Tissue. A Pilot Study

Association between COX-2 rs 6681231 Genotype and Interleukin-6 in Periodontal Connective Tissue. A Pilot Study

Effects of the Tumor Necrosis Factor-α Antagonist Adalimumab on Arterial Inflammation Assessed by Positron Emission Tomography in Patients With Psoriasis

-174G/C polymorphism in the interleukin-6 promoter is differently associated with prostate cancer incidence depending on race

Contact Info

Product

Resources

About